Is your heart functioning properly? There is a test which can measure this, which is often recommended by medical ...

Dr. Hare answers the question: 'Must I Repeat Ejection Fraction Tests?' — -- Question: Should the ejection fraction test be repeated at each visit to my doctor, or at all? Answer: The ejection ...

Heart failure with preserved ejection fraction (HFpEF) is a type of heart failure that affects the left side of the heart. It occurs when the lower left chamber of the heart, called the left ventricle ...

The Heart Failure Society of America (HFSA), the Heart Failure Association of the European Society of Cardiology (HFA of the ESC), and the Japanese Heart Failure Society (JHFS) announced today a new ...

Patients with newly diagnosed heart failure with reduced ejection fraction (HFrEF) commonly have improvements in their LVEF, but that doesn’t mean they can let their guard down, data from a large ...

Among iron-deficient patients with heart failure with reduced ejection fraction (HFrEF), receiving intravenous iron supplementation was found to be safe but resulted in mixed findings, according to a ...

Please provide your email address to receive an email when new articles are posted on . Finerenone reduced risk for CV death and worsening heart failure vs. placebo in this patient population. Pooled ...

Most trials that have shown a benefit of beta-blocker treatment after myocardial infarction included patients with large myocardial infarctions and were conducted in an era before modern ...

HFpEF prevalence in INOCA patients may be higher than expected. Learn why early screening could transform care.

Heart failure is a heterogeneous syndrome. Approximately 30–50% of patients with heart failure have normal or near normal left ventricle function. Several epidemiological studies confirm that the ...

Objective: To provide an overview of heart failure with preserved ejection fraction (HFPEF), as well as its pathophysiology, diagnosis, and clinical evidence regarding its pharmacologic management.

Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, ...